DGX vs KROS · P/E 22, rev $5.94B vs rev $32.0K
Quest Diagnostics Incorporated (DGX) versus Keros Therapeutics Inc (KROS) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Keros Therapeutics Inc (KROS) is a biotechnology company listed on US.
Latest reported DGX revenue for 2026-06-30 was $5.94B. Net income was $572.0M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
Latest reported KROS revenue for 2026-06-30 was $32.0K. Net income was -$52.4M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. KROS currently screens at market cap $208.8M.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. KROS currently screens at market cap $208.8M.
Not investment advice. Open the DGX and KROS stock pages for the full models.
Not investment advice.